Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer

AIM: This real-world study aims to compare overall survival (OS) associated with biweekly (Q2W) versus weekly (Q1W) cetuximab dosing regimens for metastatic colorectal cancer (mCRC) treatment in the US. METHODS: Adult patients with KRAS wild-type mCRC who received cetuximab ± chemotherapy from 2013...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Himani, Han, Yimei, Sheffield, Kristin M, Cui, Zhanglin Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288952/
https://www.ncbi.nlm.nih.gov/pubmed/36705061
http://dx.doi.org/10.2217/cer-2022-0143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288952/
https://www.ncbi.nlm.nih.gov/pubmed/36705061
http://dx.doi.org/10.2217/cer-2022-0143

Ejemplares similares